A recent study evaluated the effectiveness of anifrolumab (Saphnelo®) combined with standard of care (SOC) treatments compared to SOC treatment alone in preventing organ damage. Results showed that ...
The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...
However, a newer lupus drug, anifrolumab (brand name Saphnelo), has shown promising results in reducing organ damage, according to a recent study published in Annals of the Rheumatic Diseases.
Hosted on MSN25d
Anifrolumab Tied to Less Organ Damage for Patients With LupusTHURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...
THURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...
But a newer lupus drug appears to protect patients from much of this organ damage, a new study suggests. Anifrolumab (brand name Saphnelo) reduced the risk of long-term organ damage progression by ...
Anifrolumab (brand name Saphnelo) reduced the risk of long-term organ damage progression by about 60% in patients with moderately to severely active lupus, researchers reported in a new study ...
Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in 2021 WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- Lupus can do ...
These include GSK’s Benlysta (belimumab) and AstraZeneca’s Saphnelo (anifrolumab). The market for CLE, however, has seen even less innovation. CLE is a form of lupus that primarily affects the skin, ...
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...
The study achieved its primary endpoint in eliciting a mean change from baseline using the 28-Joint Disease Activity Score. credit: Shuttertstock / jittawit21. AnaptysBio’s Phase IIb trial of its ...
Since 1983, our worldwide practice — spanning the Americas, Asia-Pacific and Europe — has guided leaders across all industries, from global corporations to emerging entrepreneurial businesses and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback